Orphan designation: recombinant human factor IX protein modified with three point mutations (dalcinonacog alfa) Treatment of haemophilia B, 20/06/2017 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 26 May 2026 - 11:03

Orphan designation: recombinant human factor IX protein modified with three point mutations (dalcinonacog alfa) Treatment of haemophilia B, 20/06/2017 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1884

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters